Reason for request
Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient. |
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
j9WxJpRg37RZa6p0
